What Facts Should You Know About Palisade Bio?

Shares of Healthcare sector company Palisade Bio moved 86.0% today, and are now trading at a price of $5.99. The small-cap stock's daily volume was 83,758,826 compared to its average volume of 1,580,354. The S&P 500 index returned a -1.1% performance.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. The company is based in Carlsbad and has 13 full time employees. Its market capitalization is $9,233,721.

The only analyst following Palisade Bio has set a target price of $25 per share, which is -76.04 away from its current price. This analyst rates the stock as buy.

Over the last year, PALI shares have gone down by -95.0%, which represents a difference of -75.8% when compared to the S&P 500. The stock's 52 week high is $81 per share and its 52 week low is $1.74. Palisade Bio has averaged free cash flows of $-9,773,500.0 over the last four years, with a mean growth rate of -209.4%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.

Date Reported Cash Flow from Operations ($ MM) Capital expenditures ($ MM) Free Cash Flow ($ MM) YoY Growth (%)
2021-12-31 -15 0 -15 -209.45
2020-12-31 -5 -0 -5 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.